Tiziana Life Sciences PLC Grant of options - Director's dealing (4431P)
August 31 2017 - 5:07AM
UK Regulatory
TIDMTILS
RNS Number : 4431P
Tiziana Life Sciences PLC
31 August 2017
Tiziana Life Sciences PLC
("Tiziana" or the "Company")
Grant of options - Director's dealing
London, 31 August 2017 - Tiziana Life Sciences plc (AIM: TILS,
the "Company"), the clinical stage biotechnology company focused on
targeted drugs to treat diseases in oncology and immunology,
announces that the Remuneration Committee proposed and the Board
has awarded the following options on 30 August 2017.
Dr Kunwar Shailubhai, the Company's Chief Executive Officer and
Chief Scientific Officer, has been awarded options over 400,000
ordinary shares in the capital of the Company. The options are
exercisable at a price of 159.5 pence per share. The options will
vest in equal tranches over four years beginning on the date of
grant. Dr Shailubhai already holds 300,000 options at an exercise
price of 50p pursuant to an award made on 25 June 2014 (of which
200,000 options are vested and 100,000 remain subject to vesting
conditions).
A further 168,000 options over ordinary shares in the capital of
the Company were granted by the Company to staff members on the
same terms and on the same date.
The Company's issued share capital comprises 123,827,938
ordinary shares of 3p each.
Including the grants noted above, the Company has granted
options over a total of 10,717,403 ordinary shares of which
4,752,500 are vested at exercise prices between 15p and GBP1.25p
per share and 5,964,903 remain subject to vesting conditions (at
potential exercise prices ranging from 15p to GBP1.925 per share).
In addition warrants to subscribe for a total of 4,239,579 ordinary
shares at exercise prices between 50p and GBP2.50 are
outstanding.
Therefore the fully diluted issued share capital of the Company
is 138,784,920 ordinary shares (assuming all options and warrants,
vested and unvested, exercised and exercisable, were
converted).
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
Contacts:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray / Jo Turner / Richard Nash +44 (0)20 7213 0880
Beaufort Securities Limited (Broker)
Saif Janjua +44 (0)20 7382 8300
FTI Consulting
Simon Conway / Natalie Garland-Collins +44 (0)20 3727 1000
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules that
treat human disease in oncology and immunology. The Company is
focused on its lead compound milciclib. The Company is also in
clinical development of foralumab. Foralumab is the only fully
human engineered anti-human CD3 antibody in clinical development.
This phase II compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as nonalcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBS),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
inflammatory bowel disease (IBD), psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable.
For more information go to
http://www.tizianalifesciences.com
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
---------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
----- --------------------------------------------------------------
a. Name Dr Kunwar Shailubhai
-------------------------------
2 Reason for
notification
----- ----------------------------- -------------------------------
a. Position/Status Chief Executive Officer
----- ----------------------------- -------------------------------
b. Initial notification/ 31 August 2017
Amendment
----- ----------------------------- -------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--------------------------------------------------------------
a. Name Tiziana Life Sciences plc
----- ----------------------------- -------------------------------
b. LEI
----- ----------------------------- -------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
----- --------------------------------------------------------------
a. Description Option
of the financial
instrument, GB00BKWNZY55
type of instrument
Identification
Code
----- ----------------------------- -------------------------------
b. Nature of the Grant of options
transaction
----- ----------------------------- -------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s)
----- ----------------------------- ------------- -------------
159.5p 400,000
------------- -------------
Aggregated
information
- Aggregated
Volume 400,000
d. - Price 159.5p
----- ----------------------------- -------------------------------
e. Date of the 31 August 2017
transaction
----- ----------------------------- -------------------------------
f. Place of the XLON
transaction
----- ----------------------------- -------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGMGFRGMDGNZM
(END) Dow Jones Newswires
August 31, 2017 06:07 ET (10:07 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024
